Ellsworth Advisors LLC Has $3.80 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Ellsworth Advisors LLC cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,570 shares of the medical research company’s stock after selling 218 shares during the period. Ellsworth Advisors LLC’s holdings in Charles River Laboratories International were worth $3,797,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Wolff Wiese Magana LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at $32,000. Versant Capital Management Inc raised its stake in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares during the period. Assetmark Inc. boosted its holdings in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. grew its stake in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at $59,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on CRL. William Blair restated an “outperform” rating on shares of Charles River Laboratories International in a report on Tuesday, January 14th. Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. TD Cowen lifted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their price target for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Finally, Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective on the stock. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average target price of $209.00.

Insider Activity at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Down 1.2 %

Charles River Laboratories International stock opened at $163.77 on Monday. The firm has a 50 day moving average price of $190.64 and a 200-day moving average price of $198.40. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $160.85 and a twelve month high of $275.00. The company has a market capitalization of $8.37 billion, a P/E ratio of 20.50, a P/E/G ratio of 6.62 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the business posted $2.72 earnings per share. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).